IHC of T-bet on an FFPE Lymphoma Tissue
|Intended Use||For In Vitro Diagnostic Use|
|Summary and Explanation||T-bet, a T-box transcription factor, is expressed in CD4+ T-lymphocytes committed to T-helper (Th)1 T-cell development from naïve T-helper precursor cells (Thp) and redirects Th2 T cells to Th1 development.
T-bet is expressed in a significant subset of B-cell lymphoproliferative disorders, particularly at an early stage of B-cell development (precursor B-cell lymphoblastic leukemia/lymphoblastic lymphoma), and B-cell neoplasms derived from mature B cells, including CLL/SLL, marginal zone lymphoma, and hairy cell leukemia. In contrast, B-cell neoplasms derived from pregerminal center or germinal center B-cells, including mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and Burkitt lymphoma are negative for T-bet. Therefore, anti-T-bet should serve as a useful marker for the diagnosis and subtyping of B-cell and T-cell lymphoproliferative disorders.
|Antibody Type||Rabbit Monoclonal||Clone||EP263|
|Localization||Nuclear||Control||Spleen, Tonsil, Cervix, Lymphoblastic lymphoma, Hairy Cel leukemia, Bladder TCC|
|Presentation||T-bet is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.|
|Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.|